Themis Bioscience GmbH

Funding (a Capricorn Consilium project)

The Client

Themis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications like Chikungunya, Zika or Dengue virus vaccines.

The Task

Following a successful start based on seed and series A funding, Themis kicked-off the series B funding activities. Capricorn Consilium has been approached for support.

The Solution

Capricorn Consilium focused on contacts to Venture Capital firms. The joint activities led to a successful series B funding.

28 November 2016
Themis Bioscience Successfully Closes 10 M EUR Financing Round